Healthcare / BiotechnologyNasdaqGS
$1.79
-0.04 (-2.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-34.9M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$168M
P/E
N/A
•EV/EBITDA
N/A
•ROE
226.6%
↑Gross Margin
N/A
•Debt/Equity
-1.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-61.7%
FCF CAGR
—
FCF margin
-1252.6%
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.8M · net income $-49.2M · FCF $-34.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.8M | $2.8M | $12.6M | $51.9M | $49.6M |
| Net Income | $-49.2M | $-49.2M | $-49.5M | $-7.6M | $-58.1M |
| EBITDA | $-43.6M | $-43.6M | $-46.9M | $-5.5M | $-12.3M |
| EPS | -0.55 | -0.55 | -0.61 | -0.09 | -0.73 |
| Operating Margin | -1916.9% | -1916.9% | -408.7% | -24.4% | -33.1% |
| Net Margin | -1764.5% | -1764.5% | -392.0% | -14.6% | -117.2% |
| Balance Sheet | |||||
| Debt/Equity | -1.04 | -1.04 | 3.51 | 0.77 | 0.78 |
| Current Ratio | 1.27 | 1.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-34.9M | $-34.9M | $-7.3M | $-52.9M | $-20.3M |
| Returns | |||||
| ROE | 226.6% | 226.6% | -560.0% | -14.6% | -107.3% |
| Valuation | |||||
| P/B | — | — | 17.16 | 4.73 | 4.91 |
| Growth & Yield | |||||
| Revenue Growth | -77.9% | -77.9% | -75.7% | 4.7% | — |
| EPS Growth | 9.8% | 9.8% | -577.8% | 87.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.61 → -0.55
Residual
-18.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.